Bulgari apologizes to China for listing Taiwan as a country after online backlash

1:28AwomanwalksbytheBulgaristoreatahigh-endshoppingmallinBeijing,Wednesday,July12,2023.Italianluxury ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




leisure time

author：focus    Page View：82
Adam's take main illustration
Molly Ferguson/STAT

Biotech is awash in PIPEs.

The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

advertisement

Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Palantir health business leans on meeting customers’ needs
Next article： Drug repurposing or repositioning? The language matters